What is the long-term trend for Esperion Therapeutics's other non-current liabilities?

Over 3 years (2020 to 2025), Esperion Therapeutics's other non-current liabilities has grown at a 89.2% compound annual growth rate (CAGR), from $1.29M to $8.74M.

What does other non-current liabilities mean?

Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.

Esperion Therapeutics ESPR Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

AmgenAMGN

$2.37B+7.0%

Regeneron PharmaceuticalsREGN

$2.13B+27.0%

Lexicon PharmaceuticalsLXRX

$6.38M+20.3%

Zevra Therapeutics, Inc.ZVRA

$1.86M-61.9%

Eton Pharmaceuticals, Inc.ETON

$3.54M-14.8%

BridgeBio PharmaBBIO

$229K-34.9%

Other financials

Income statement

See full

Revenue$80.1M+23.2%

Operating income-$6.6M+70.2%

Net income-$25.2M+37.7%

EPS (diluted)-$0.10+52.4%

Balance sheet

See full

Cash & equivalents$156.2M+36.2%

Total debt$155.2M+6.1%

Total equity-$307.9M+27.8%

Total assets$462.5M+42.7%

Cash flow

See full

Operating cash flow-$27.7M-22.5%

CapEx$189.0K—

Free cash flow-$27.9M-23.3%

Valuation

See full

Market cap$811.73M+283%

Enterprise value$810.81M+233%

P/S1.9×+1.1×

Profitability

See full

Operating margin18.1%+12.7pp

Net margin-34.8%+8.0pp

FCF margin-30.7%—

Returns & leverage

See full

Return on equity-260.8%—

Debt / equity0.8×—

Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Esperion Therapeutics's other non-current liabilities?: Esperion Therapeutics (ESPR) reported other non-current liabilities of $8.74M in Q1 2026.
What is the long-term trend for Esperion Therapeutics's other non-current liabilities?: Over 3 years (2020 to 2025), Esperion Therapeutics's other non-current liabilities has grown at a 89.2% compound annual growth rate (CAGR), from $1.29M to $8.74M.
What does other non-current liabilities mean?: Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.